Artificial Blood and Plasma 2018 - Global Markets to 2027

Dublin, April 05, 2018 -- The "Artificial Blood and Plasma: Global Markets to 2027" report has been added to ResearchAndMarkets.com's offering.

The report provides a detailed overview of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status and the potential commercial market for artificial blood products.
The report includes a discussion of artificial oxygen carrier products manufacturing, product features, technology and methodology used, available results of laboratory and clinical tests, product effectiveness, and factors that are affecting the market. Further, it explains the major drivers and regional dynamics of the global artificial blood market and current trends within the industry.

The report concludes with a special look at the potential artificial blood products that may enter the blood market postapproval from international authorities. Detailed profiles of the key players in the global artificial blood market and the current development stages of their products have been included.

Report Includes:

• 144 tables
• An overview of global market for artificial blood plasma
• Analyses of global market trends, with projections of compound annual growth rates (CAGRs) through 2027
• Identification of growth-driving factors influencing the artificial blood plasma market, as well as opportunities, restraints, and technological developments
• Profiles of leading companies in the market, including Alliance Pharmaceutical Corp., Baxter Healthcare Corp., Northfield Laboratories Inc., Sanguine Biosciences, and Therapure Biopharma Inc.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview
Is There a Problem with Human Blood?
Emerging Needs for Artificial Blood
Artificial Blood Will Be Useful in Dealing With the Risks of Infection
Artificial Blood Will Help to Decrease the Load on Donor Blood Supply
Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System
Artificial Blood Has the Potential to Lower Costs of the Blood System
Hurdles in the Development of Artificial Blood Products
Ideal Characteristics of Artificial Blood
Artificial Blood Over Human Blood
Challenges in Artificial Blood Development

Chapter 4 Market Estimation
Market Dynamics: Factors and Impact Analysis
Time factor
Product Preference
Regulatory Approvals
Product Demand
Product Acceptance
Cost and Effectiveness
Intense Competition in the Market
Clinical Trials
Technologies
Product Pricing
Patient Group
Global Potential Market
Surgeries and Death Cases
Market Penetration

Chapter 5 Market by Source
Introduction
Artificial Blood Developed From Human Blood
Artificial Blood Developed From Animal Blood
Artificial Blood Developed Using Recombinant Technology
Surface Modified Hemoglobin
Cross-Linked Hemoglobin
Polymerized Hemoglobin

Chapter 6 Market by Type
Introduction
Perfluorocarbon Emulsions
General Characteristics of Perfluorocarbons
Emulsion Selection
Historical Developments of Perfluorocarbon Emulsions
First Generation of PFCs
Second Generation of PFCs
Third Generation of PFCs
Hemoglobin Based Oxygen Carriers
General Characteristics of HBOCs
Historical Events: - Hemoglobin Solutions

Chapter 7 Market Breakdown by Application
Introduction
Surgeries
Emergency Resuscitation
For Short-term Use
Where More Effective Than Human Blood
Rejections Due to Religious Beliefs
Global Potential Artificial Blood Market, by Application

Chapter 8 Market Breakdown by Region

Chapter 9 Regulation and Patent Review
Introduction
FDA Regulation
FDA Good Manufacturing Practices and Reporting
Patent Review

Chapter 10 Competitive Landscape
Introduction

Chapter 11 Product Analysis

• Alliance Pharmaceutical Corp
• Baxter Healthcare Corp.
• Biopure Corp.
• Fluoro2 Therapeutics,Inc.
• Hemobiotech, Inc.
• Northfield Laboratories Inc.
• Nuvox Pharma Llc.
• Prolong Pharmaceuticals, Llc
• Sangart, Inc.
• Sanguine Biosciences
• Tenax Therapeutics Inc.
• Therapure Biopharma Inc.

For more information about this report visit https://www.researchandmarkets.com/research/jf5hkn/artificial_blood?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Biomaterials